Spots Global Cancer Trial Database for Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma

Official Title: Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma

Study ID: NCT00179881

Conditions

Brain Stem Neoplasms, Primary

Neoplasms, Brain Stem

Interventions

Carboplatin

Thalomid

External Beam Radiation Therapy

Study Description

Brief Summary: Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the process of new blood vessel formation). If a tumor does not have blood vessels providing oxygen and nutrients, it will not be able to grow. This research will look at how combining the effects of thalidomide (preventing tumor growth) with the tumor killing effect of carboplatin effects the long-term outlook for patients with these tumors. This study will try to find out how well Thalomid™ and carboplatin combined with radiation therapy works in treating children newly diagnosed with brain stem glioma. This study will look at how well Thalomid ™ and carboplatin work in patients with recurrent brain stem glioma. This study will also look at any side effects of these treatments.

Detailed Description: